A test conducted by Cannabics Pharmaceuticals in Israel at its High Through-put Screening (HTS) facility reveals that cannabinoids CBC and CBG both exhibit anti-tumor properties after being tested on human Gastrointestinal Cancer Cells.
CBC is a non-psychoactive component present in cannabis plant. It is also a naturally occurring phytocannabinoid. The component demonstrates a host of therapeutic properties and also promotes analgesic, anti-inflammatory, and antimicrobial activity. It is found more in younger plants in small quantities.
“Researchers from Cannabics Pharmaceuticals studied the necrotic effects of various cannabinoids on cancer cells during the study. Both CBC and CBG induced higher rates of necrosis in cancer cells during the tests.”
Statement from the Head of Cannabidiol Research on CBC and CBG
The head of cannabidiol research, Dr. Yaakov Waksman said that the results demonstrate that there exists a correlation between the topological polar surface area (TPSA) value of a cannabinoid and its ability to induce anti-tumor activity.
This further diminished the viability rates of the cancer cells tested. CBG and CBC were both found to have TPSA value. This thereby, allows the molecule of a cannabinoid to penetrate the membrane of cancer cells.
However, their acidic forms do not exhibit this property. This could explain the difference in the activity rates noted during the tests.
The Co-Founder and CTO of Cannabics Pharmaceuticals, Dr. Eyal Ballan shared his insights on the tests conducted. He said he was intrigued by the results obtained in the lab.
He said that his main motive is to consider placing an emphasis on this organ system and to explore the differential anti-tumor properties of cannabinoids.
He stressed that these results are preliminary and vindicate the vision of the company. There are plans to personalize into cannabinoid-based cancer treatments.
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. is a US public company that is working towards creating a platform that can leverage artificial intelligence and drug-screening tools for developing cannabinoid-based therapies for the treatment of cancer.
The approach is to be more specific to the profile of a patient. The company intends to develop tools for assessing its effectiveness by incorporating the factor of personalization.
Cannabics is focusing on integrating cannabinoids with cancer treatment. The company has its Research and Development unit in Israel. The unit has obtained a permit from the Ministry of Health for conducting scientific and clinical research on cancer and cannabinoid formulations.